Home › Companies › SAREPTA THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and SAREPTA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 6, 2024: 6 items on SAREPTA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 4 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore SAREPTA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are SAREPTA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Douglas S. Ingram | 71,684,003 | 1,141,805 | 16,569 | -- | 8,161,580 | 98% | Elected | — |
| Elect Director: Hans Wigzell, M.D., Ph.D. | 62,357,683 | 10,424,422 | 60,272 | -- | 8,161,580 | 86% | Elected | — |
| Elect Director: Kathryn J. Boor, Ph.D. | 66,169,655 | 6,656,367 | 16,355 | -- | 8,161,580 | 91% | Elected | — |
| Elect Director: Michael Chambers | 71,087,155 | 1,737,715 | 17,507 | -- | 8,161,580 | 98% | Elected | — |
| 2. Advisory Vote to Approve Named Executive Officer Compensation | 63,631,197 | 9,004,619 | 206,561 | -- | 8,161,580 | 88% | Approved | — |
| 3. Ratification of KPMG as the Company's Independent Registered Public Accounting Firm | 77,132,548 | 3,758,836 | 112,573 | -- | -- | 95% | Approved | — |
Source: SAREPTA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
Each item below shows how the 427 asset managers that disclosed a SAREPTA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Douglas S. Ingram
SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Douglas S. Ingram”): 71,684,003 for, 1,141,805 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,724,218 | 0 | 0 | 0 | For |
| Capital Group | 3,220,374 | 0 | 0 | 0 | For |
| Fidelity | 3,027,757 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,936,541 | 0 | 0 | 0 | For |
| BlackRock | 2,487,598 | 0 | 0 | 0 | For |
| AMCAP FUND | 1,540,079 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,404,446 | 0 | 0 | 0 | For |
| BNY Mellon | 784,664 | 0 | 0 | 0 | For |
| JPMorgan | 712,675 | 0 | 0 | 0 | For |
| State Street | 649,562 | 961 | 0 | 0 | For |
| Federated Hermes | 609,175 | 0 | 0 | 0 | For |
| Thrivent | 597,457 | 0 | 0 | 0 | For |
| Charles Schwab | 587,119 | 0 | 0 | 0 | For |
| Hartford | 549,206 | 0 | 0 | 0 | For |
| TIAA | 514,069 | 0 | 0 | 0 | For |
| Jackson National | 322,257 | 0 | 0 | 0 | For |
| Aberdeen | 191,857 | 0 | 0 | 0 | For |
| Voya | 165,265 | 0 | 0 | 0 | For |
| Allspring | 162,820 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 155,326 | 0 | 0 | 0 | For |
| Equitable | 147,874 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 147,737 | 0 | 0 | 0 | For |
| Dimensional | 140,107 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 135,730 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 121,148 | 0 | 0 | 0 | For |
Fund voting reports, all 111 managers: 34,260,072 for, 963 against, 3,543 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 571,400 | 0 | 0 | 0 | For |
| HOWLAND CAPITAL MANAGEMENT LLC | 1,632 | 0 | 0 | 0 | For |
| Evernest Financial Advisors, LLC | 161 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 25 | 0 | 0 | 0 | For |
| Keel Point, LLC | 16 | 0 | 0 | 0 | For |
| Warren Street Wealth Advisors, LLC | 12 | 0 | 0 | 0 | For |
Institutional-manager reports, all 6 managers: 573,246 for.
Combines 8 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Hans Wigzell, M.D., Ph.D.
SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Hans Wigzell, M.D., Ph.D.”): 62,357,683 for, 10,424,422 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,724,218 | 0 | 0 | 0 | For |
| Capital Group | 3,220,374 | 0 | 0 | 0 | For |
| Fidelity | 3,020,435 | 7,322 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,936,541 | 0 | 0 | 0 | For |
| BlackRock | 2,487,598 | 0 | 0 | 0 | For |
| AMCAP FUND | 1,540,079 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 1,404,446 | 0 | 0 | Against |
| BNY Mellon | 784,664 | 0 | 0 | 0 | For |
| JPMorgan | 712,675 | 0 | 0 | 0 | For |
| State Street | 13,036 | 637,487 | 0 | 0 | Against |
| Federated Hermes | 609,175 | 0 | 0 | 0 | For |
| Thrivent | 597,457 | 0 | 0 | 0 | For |
| Charles Schwab | 587,119 | 0 | 0 | 0 | For |
| Hartford | 549,206 | 0 | 0 | 0 | For |
| TIAA | 514,069 | 0 | 0 | 0 | For |
| Jackson National | 162,613 | 159,644 | 0 | 0 | Mixed |
| Aberdeen | 191,857 | 0 | 0 | 0 | For |
| Voya | 165,265 | 0 | 0 | 0 | For |
| Allspring | 162,820 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 155,326 | 0 | 0 | 0 | For |
| Equitable | 82,185 | 65,689 | 0 | 0 | Mixed |
| Columbia Threadneedle | 0 | 147,737 | 0 | 0 | Against |
| Dimensional | 140,107 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 135,730 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 121,148 | 0 | 0 | 0 | For |
Fund voting reports, all 111 managers: 31,091,409 for, 3,169,626 against, 3,543 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 571,400 | 0 | 0 | 0 | For |
| HOWLAND CAPITAL MANAGEMENT LLC | 1,632 | 0 | 0 | 0 | For |
| Evernest Financial Advisors, LLC | 161 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 25 | 0 | 0 | 0 | For |
| Keel Point, LLC | 16 | 0 | 0 | 0 | For |
| Warren Street Wealth Advisors, LLC | 12 | 0 | 0 | 0 | For |
Institutional-manager reports, all 6 managers: 573,246 for.
Combines 7 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Kathryn J. Boor, Ph.D.
SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kathryn J. Boor, Ph.D.”): 66,169,655 for, 6,656,367 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,724,218 | 0 | 0 | 0 | For |
| Capital Group | 3,220,374 | 0 | 0 | 0 | For |
| Fidelity | 3,020,435 | 7,322 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,936,541 | 0 | 0 | 0 | For |
| BlackRock | 2,487,598 | 0 | 0 | 0 | For |
| AMCAP FUND | 1,540,079 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 1,404,446 | 0 | 0 | Against |
| BNY Mellon | 784,664 | 0 | 0 | 0 | For |
| JPMorgan | 712,675 | 0 | 0 | 0 | For |
| State Street | 649,054 | 1,469 | 0 | 0 | For |
| Federated Hermes | 609,175 | 0 | 0 | 0 | For |
| Thrivent | 597,457 | 0 | 0 | 0 | For |
| Charles Schwab | 587,119 | 0 | 0 | 0 | For |
| Hartford | 549,206 | 0 | 0 | 0 | For |
| TIAA | 514,069 | 0 | 0 | 0 | For |
| Jackson National | 162,613 | 159,644 | 0 | 0 | Mixed |
| Aberdeen | 191,857 | 0 | 0 | 0 | For |
| Voya | 165,265 | 0 | 0 | 0 | For |
| Allspring | 162,820 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 155,326 | 0 | 0 | 0 | For |
| Equitable | 82,185 | 65,689 | 0 | 0 | Mixed |
| Columbia Threadneedle | 147,737 | 0 | 0 | 0 | For |
| Dimensional | 140,107 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 135,730 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 121,148 | 0 | 0 | 0 | For |
Fund voting reports, all 111 managers: 31,942,195 for, 2,318,840 against, 3,543 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 571,400 | 0 | 0 | 0 | For |
| HOWLAND CAPITAL MANAGEMENT LLC | 1,632 | 0 | 0 | 0 | For |
| Evernest Financial Advisors, LLC | 161 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 25 | 0 | 0 | 0 | For |
| Keel Point, LLC | 16 | 0 | 0 | 0 | For |
| Warren Street Wealth Advisors, LLC | 12 | 0 | 0 | 0 | For |
Institutional-manager reports, all 6 managers: 573,246 for.
Combines 8 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Michael Chambers
SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Chambers”): 71,087,155 for, 1,737,715 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,724,218 | 0 | 0 | 0 | For |
| Capital Group | 3,220,374 | 0 | 0 | 0 | For |
| Fidelity | 3,020,435 | 7,322 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,936,541 | 0 | 0 | 0 | For |
| BlackRock | 2,487,598 | 0 | 0 | 0 | For |
| AMCAP FUND | 1,540,079 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,064,377 | 340,069 | 0 | 0 | Mixed |
| BNY Mellon | 784,664 | 0 | 0 | 0 | For |
| JPMorgan | 712,675 | 0 | 0 | 0 | For |
| State Street | 649,835 | 688 | 0 | 0 | For |
| Federated Hermes | 609,175 | 0 | 0 | 0 | For |
| Thrivent | 597,457 | 0 | 0 | 0 | For |
| Charles Schwab | 587,119 | 0 | 0 | 0 | For |
| Hartford | 549,206 | 0 | 0 | 0 | For |
| TIAA | 514,069 | 0 | 0 | 0 | For |
| Jackson National | 322,257 | 0 | 0 | 0 | For |
| Aberdeen | 191,857 | 0 | 0 | 0 | For |
| Voya | 165,265 | 0 | 0 | 0 | For |
| Allspring | 162,820 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 155,326 | 0 | 0 | 0 | For |
| Equitable | 82,185 | 65,689 | 0 | 0 | Mixed |
| Columbia Threadneedle | 147,737 | 0 | 0 | 0 | For |
| Dimensional | 140,107 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 135,730 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 121,148 | 0 | 0 | 0 | For |
Fund voting reports, all 111 managers: 33,698,911 for, 562,124 against, 3,543 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 571,400 | 0 | 0 | 0 | For |
| HOWLAND CAPITAL MANAGEMENT LLC | 1,632 | 0 | 0 | 0 | For |
| Evernest Financial Advisors, LLC | 161 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 25 | 0 | 0 | 0 | For |
| Keel Point, LLC | 16 | 0 | 0 | 0 | For |
| Warren Street Wealth Advisors, LLC | 12 | 0 | 0 | 0 | For |
Institutional-manager reports, all 6 managers: 573,246 for.
Combines 20 wordings of this item as funds reported it.
88% Approved · of votes cast
Description as filed by funds: advisory vote to approve, on a non-binding basis, named executive officer compensation
SAREPTA THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote to Approve Named Executive Officer Compensation”): 63,631,197 for, 9,004,619 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2023.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,724,218 | 0 | 0 | 0 | For |
| Capital Group | 3,220,374 | 0 | 0 | 0 | For |
| Fidelity | 3,027,757 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,936,541 | 0 | 0 | 0 | For |
| BlackRock | 2,487,598 | 0 | 0 | 0 | For |
| AMCAP FUND | 1,540,079 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,404,446 | 0 | 0 | 0 | For |
| BNY Mellon | 784,664 | 0 | 0 | 0 | For |
| JPMorgan | 712,675 | 0 | 0 | 0 | For |
| State Street | 650,523 | 0 | 0 | 0 | For |
| Federated Hermes | 609,175 | 0 | 0 | 0 | For |
| Thrivent | 597,457 | 0 | 0 | 0 | For |
| Charles Schwab | 587,119 | 0 | 0 | 0 | For |
| Hartford | 549,206 | 0 | 0 | 0 | For |
| TIAA | 514,069 | 0 | 0 | 0 | For |
| Jackson National | 321,055 | 1,202 | 0 | 0 | For |
| Aberdeen | 191,857 | 0 | 0 | 0 | For |
| Voya | 165,265 | 0 | 0 | 0 | For |
| Allspring | 162,820 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 155,326 | 0 | 0 | 0 | For |
| Equitable | 147,874 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 147,737 | 0 | 0 | 0 | For |
| Dimensional | 0 | 140,107 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 135,730 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 121,148 | 0 | 0 | 0 | For |
Fund voting reports, all 113 managers: 33,806,961 for, 553,205 against, 2,144 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| OAK RIDGE INVESTMENTS LLC | 17,000,000 | 0 | 0 | 0 | For |
| Capital Group | 4,818,072 | 0 | 0 | 0 | For |
| Janus Henderson | 4,781,447 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 3,487,894 | 0 | 0 | 0 | For |
| Wellington | 3,137,872 | 0 | 0 | 0 | For |
| BlackRock | 2,769,439 | 1,064 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 0 | 2,437,500 | 0 | 0 | Against |
| T. Rowe Price | 2,426,661 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 1,919,835 | 0 | 0 | 0 | For |
| State Street | 1,911,280 | 0 | 0 | 0 | For |
| JPMorgan | 1,739,786 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,519,615 | 0 | 0 | 0 | For |
| Fidelity | 1,348,843 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 1,033,151 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 928,537 | 0 | 0 | 0 | For |
| BNY Mellon | 647,133 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 0 | 610,500 | 0 | 0 | Against |
| Federated Hermes | 609,188 | 0 | 0 | 0 | For |
| Thrivent | 606,735 | 0 | 0 | 0 | For |
| Charles Schwab | 590,154 | 0 | 0 | 0 | For |
| Camber Capital Management LP | 585,000 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 571,400 | 0 | 0 | 0 | For |
| Nuveen | 542,059 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 540,902 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 470,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 340 managers: 61,549,819 for, 5,992,887 against, 159,604 abstained, 1,189 not voted, 8 unknown. Showing the 25 largest; see all in the interactive database.
Combines 7 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2024
SAREPTA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of KPMG as the Company's Independent Registered Public Accounting Firm”): 77,132,548 for, 3,758,836 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of KPMG as the Company's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ended December 31, 2024.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,724,218 | 0 | 0 | 0 | For |
| Capital Group | 3,220,374 | 0 | 0 | 0 | For |
| Fidelity | 3,027,757 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,936,541 | 0 | 0 | 0 | For |
| BlackRock | 2,487,598 | 0 | 0 | 0 | For |
| AMCAP FUND | 1,540,079 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,404,446 | 0 | 0 | 0 | For |
| BNY Mellon | 784,664 | 0 | 0 | 0 | For |
| JPMorgan | 712,675 | 0 | 0 | 0 | For |
| State Street | 648,003 | 2,520 | 0 | 0 | For |
| Federated Hermes | 609,175 | 0 | 0 | 0 | For |
| Thrivent | 597,457 | 0 | 0 | 0 | For |
| Charles Schwab | 587,119 | 0 | 0 | 0 | For |
| Hartford | 549,206 | 0 | 0 | 0 | For |
| TIAA | 514,069 | 0 | 0 | 0 | For |
| Jackson National | 322,257 | 0 | 0 | 0 | For |
| Aberdeen | 191,857 | 0 | 0 | 0 | For |
| Voya | 165,265 | 0 | 0 | 0 | For |
| Allspring | 162,820 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 155,326 | 0 | 0 | 0 | For |
| Equitable | 147,874 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 147,737 | 0 | 0 | 0 | For |
| Dimensional | 140,107 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 135,730 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 121,148 | 0 | 0 | 0 | For |
Fund voting reports, all 113 managers: 34,134,901 for, 225,265 against, 2,144 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 571,400 | 0 | 0 | 0 | For |
| HOWLAND CAPITAL MANAGEMENT LLC | 1,632 | 0 | 0 | 0 | For |
| Evernest Financial Advisors, LLC | 161 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 25 | 0 | 0 | 0 | For |
| Keel Point, LLC | 16 | 0 | 0 | 0 | For |
| Warren Street Wealth Advisors, LLC | 12 | 0 | 0 | 0 | For |
Institutional-manager reports, all 6 managers: 573,246 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 94,490,157 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.35% |
| 2 | Capital Group | 3.41% |
| 3 | Fidelity | 3.20% |
| 4 | JANUS INVESTMENT FUND | 3.11% |
| 5 | BlackRock | 2.63% |
| 6 | AMCAP FUND | 1.63% |
| 7 | T. Rowe Price | 1.49% |
| 8 | BNY Mellon | 0.83% |
| 9 | JPMorgan | 0.75% |
| 10 | State Street | 0.69% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | OAK RIDGE INVESTMENTS LLC | 17.99% |
| 2 | Capital Group | 5.10% |
| 3 | Janus Henderson | 5.06% |
| 4 | Avoro Capital Advisors LLC | 3.69% |
| 5 | Wellington | 3.32% |
| 6 | BlackRock | 2.93% |
| 7 | FARALLON CAPITAL MANAGEMENT LLC | 2.58% |
| 8 | T. Rowe Price | 2.57% |
| 9 | EcoR1 Capital, LLC | 2.03% |
| 10 | State Street | 2.02% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Shares Issued and Outstanding 3/31/2024 | 100.00% | DEF14A |
| BlackRock | 13.97% | 13F |
| Vanguard Group | 11.45% | 13F |
| Janus Henderson Group plc, 201 Bishopsgate, London, EC2M 3AE, United Kingdom | 5.66% | DEF14A |
| Capital International Investors | 5.02% | DEF14A |
| Wellington Management | 3.44% | 13F |
| Richard J. Barry | 3.43% | DEF14A |
| Douglas Ingram | 2.74% | DEF14A |
| Citadel Advisors | 2.26% | 13F |
| State Street | 2.25% | 13F |
Percentages above are of 94,490,157 shares outstanding, as reported by SAREPTA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SAREPTA THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At SAREPTA THERAPEUTICS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 427 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 3,110 separate fund positions. On the most widely held item on that ballot — advisory vote to approve, on a non-binding basis, named executive officer compensation — SAREPTA THERAPEUTICS INC.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: SAREPTA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
SAREPTA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.